Clinical Trials
1
Active:1
Completed:0
Trial Phases
0 Phases
Drug Approvals
6
FDA:5
NMPA:1
Drug Approvals
Telavancin Hydrochloride for Injection
- Product Name
- 注射用盐酸替拉凡星
- Approval Number
- 国药准字HJ20250017
- Approval Date
- Feb 11, 2025
NMPA
Clinical Trials
No trials found
News
Tabuk Launches Vibativ Antibiotic in Saudi Arabia to Combat Multidrug-Resistant Infections
Tabuk Pharmaceutical Manufacturing Company has launched Vibativ (telavancin) injection in Saudi Arabia through an exclusive partnership with Cumberland Pharmaceuticals, targeting hospital-acquired pneumonia and serious skin infections.